Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice: Results From a Nationwide Series of 236 Patients

Blood Cancer Journal - United States
doi 10.1038/s41408-018-0125-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group

Cancer
Cancer ResearchOncology
2018English

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Chemotherapy: Open Access
2017English

Successful Delivery After Planned Discontinuation of Imatinib in a Patient With Chronic Myeloid Leukemia

Internal Medicine
Internal MedicineMedicine
2009English

Treatment of Chronic Myeloid Leukemia With Generic Imatinib in Patients From Northeastern Part of India

International Journal of Research in Pharmaceutical Sciences
ToxicologyPharmaceuticsPharmacology
2019English

Satisfaction With Information on Nilotinib Treatment in Chronic Myeloid Leukemia Patients

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2019English

Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia

Current Oncology Reports
Oncology
2018English

Molecular Monitoring of Therapeutic Milestones and Clinical Outcomes in Patients With Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

Treatment-Related Acute Myeloid Leukemia in a Chronic Lymphocytic Leukemia Patient: Role of Fludarabine?

Therapeutic Advances in Hematology
Hematology
2015English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy